Eli Lilly has agreed to acquire AtaiBeckley for up to $3.8 billion (€3.3 billion), turning a psychedelic drug developer built from German and British roots into one of the sector’s largest pharmaceutical takeovers.Read More
Lilly buys Europe-rooted AtaiBeckley for up to $3.8B
